Fiction: ‘Daikon' by Samuel Hawley
But will the Japanese understand what they have and know how to use it? The novel centers on two men who are uneasily allied by the discovery at the crash site. Lt. Col. Shingen Sagara is a staunch militarist who recognizes the bomb as one of the devastating 'new-type' weapons that have been rumored about but generally thought to be years from arrival. He conscripts Keizo Kan, a physicist in Project Ni-Go (Japan's less successful version of the Manhattan Project), to study the bomb and prepare it for immediate use against the country that created it.
'Daikon'—the word, meaning radish, becomes the bomb's codename—unfolds like a detective novel, as Kan works backward to grasp how the weapon was made. Mr. Hawley has previously written nonfiction (including 'The Imjin War' from 2005, a history of Japanese conquest in the 16th century) and he is a fluent explainer of complex subjects. The captured bomb is technologically identical to the one used on Hiroshima. It contains rings of enriched uranium that are shot at each other inside a tube, a process not unlike the firing of a gun. Kan is staggered by the design that is at once ingenious and almost rudimentary.
The story barrels ahead urgently, as the bombings of Hiroshima and Nagasaki take place while Kan is working. Sagara becomes desperate to launch a reprisal that will thwart Japan's 'surrender faction' and extend the war to its brutal, bitter end. Kan finds himself bound to the bomb's fate, and thus to the war's. He has a connection to the U.S., having studied physics under Robert Oppenheimer at Berkeley. He is also deeply affected by the death of his daughter, who was killed in the U.S. Air Force's firebombing of Tokyo. Duty, anger, sorrow, conscience and even hope mix together to form the novel's bracingly intimate ending. Even in alternate histories, it is startling to consider how single decisions can decide worldwide outcomes.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Long Covid Patients Can Sign up for Remote Clinical Trial Notification, Announces CareEvolution
At-home participation in a study by Scripps Research and Schmidt Initiative for Long Covid powered by CareEvolution's MyDataHelps® platform ANN ARBOR, Mich., August 05, 2025--(BUSINESS WIRE)--Long Covid patients around the U.S. looking to participate in a clinical trial from home can sign up to be notified when an upcoming study conducted by scientists at Scripps Research and supported by the Schmidt Initiative for Long Covid (SILC) opens. Patients can sign up on the Long Covid Treatment Trial (LoCITT) website. The upcoming study, powered by the MyDataHelps platform from CareEvolution, is a fully remote clinical trial investigating the efficacy of a repurposed drug for treating Long COVID. It will enroll 1,000 Long Covid patients from across the U.S. The app-based study enables participants to enroll and participate in all trial activities without having to visit a trial clinic. "Decentralized trials broaden reach, speed timelines and yield richer real-world evidence," said Vik Kheterpal, MD, a principal at CareEvolution. "LoCITT will help advance how efficiently we can run trials as we seek treatments for complex, heterogeneous conditions like Long Covid." Long Covid, which has affected the lives of 400 million people worldwide and costs the global economy an estimated $1 trillion per year, can often cause symptoms that make mobility and travel challenging for patients who want to participate in trials. The forthcoming Scripps Research-led trial will rely on the LoCITT platform to enroll patients, distribute drug candidates and placebos, as well as collect and evaluate trial data. "For people with severe Long Covid, travel can be dangerous," said Julia Moore Vogel, senior program director at the Scripps Research Translational Institute. "LoCITT enables even patients with the most severe symptoms to join the search for answers." Moore Vogel is co-principal investigator of the study alongside Scripps Research executive vice president Eric Topol. Remote trials, which eliminate the need for patients to report to clinics, enable easier and broader participation. Conducting a Long Covid trial remotely will also allow more representative cohorts—potentially leading to more generalizable findings. "We need aggressive, rapid efforts to turn the tide on this very difficult condition for all the patients who struggle with it," said John Redd, CEO of SILC. "We're hopeful that a remote trial will help us find effective treatments more quickly." CareEvolution adapted its existing MyDataHelps decentralized clinical trial platform specifically for the LoCITT trial, with the potential for it to be used by other research efforts. The platform will allow for patients to be screened, enrolled and randomized more swiftly. Potential treatments and placebos will be mailed directly to the participant's home, along with wearable devices and other technologies to collect patient data. CareEvolution's user-friendly platform allows patients to check their eligibility, provide consent electronically and respond to baseline and ongoing surveys about their symptoms. Patients selected for the study will receive wrist devices to monitor their heart rates, activity and sleep, potentially enabling the development of digital biomarkers for Long Covid and related conditions like myalgic encephalomyelitis (ME), which can cause debilitating fatigue, and postural orthostatic tachycardia syndrome (POTS), which can cause dizziness, fatigue and a rapid heart rate upon standing up. The data from the devices will be uploaded to LoCITT. Prospective participants who are 18 years of age or older and who believe they have Long Covid can sign up at to be notified when the Scripps clinical trial opens. About CareEvolution We Connect Healthcare. MyDataHelps®, our digital clinical trials platform, accelerates healthcare innovation by empowering researchers to configure and launch studies in hours. We enable anyone, anywhere to be able to participate in research using participant centric design that integrates surveys, wearable and sensor data, EHR connectivity, and participant engagement tools to generate robust real-world longitudinal data. Trusted by over 2.5 million participants enrolled in longitudinal initiatives sponsored by health systems, academic institutions, life science companies, foundations, and public health agencies, CareEvolution advances precision health and helps close critical gaps in our collective understanding of complex conditions. For more information please visit About the Schmidt Initiative for Long Covid The Schmidt Initiative for Long Covid (SILC) advances clinical care for Long Covid patients globally. The nonprofit organization, founded in 2023 by philanthropists Eric and Wendy Schmidt, works to raise the level of Long Covid care and understanding around the world, connecting specialists and primary care providers to support patients and share knowledge virtually, in real time. For more information, visit About Scripps Research Scripps Research is an independent, nonprofit biomedical institute ranked one of the most influential in the world for its impact on innovation by Nature Index. We are advancing human health through profound discoveries that address pressing medical concerns around the globe. Our drug discovery and development division, Calibr-Skaggs, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 US programs for chemistry and biological sciences. Learn more at View source version on Contacts CareEvolutionpr@ Swati Pandey, SILCspandey@ Anna Andersen, Scripps Researchaanders@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
2 hours ago
- New York Times
A Nuclear Reactor on the Moon? Come Again?
The acting administrator of NASA has issued a directive to fast-track efforts to put a nuclear reactor on the moon. 'To properly advance this critical technology to be able to support a future lunar economy, high power energy generation on Mars, and to strengthen our national security in space, it is imperative the agency move quickly,' Sean Duffy, the secretary of transportation whom President Trump appointed last month as temporary leader of the space agency, wrote in the directive, which was sent out on Thursday. Politico was first to report on the directive. In it, Mr. Duffy cites plans by China and Russia to put a reactor on the moon by the mid-2030s as part of a partnership to build a base there. If they were first, China and Russia 'could potentially declare a keep-out zone' that would inhibit what the United States could do there, Mr. Duffy said. The directive calls for the appointment of a NASA official to oversee the effort within 30 days and for a request seeking proposals from commercial companies to be issued within 60 days. The reactor will be required to generate at least 100 kilowatts of electrical power — enough for about 80 households in the United States — and to be ready to launch in late 2029. One lunar day lasts four weeks on Earth — two weeks of continual sunshine followed by two weeks of cold darkness. That harsh cycle makes it difficult for a spacecraft or a moon base to survive with just solar panels and batteries. Current exploration efforts, both by NASA and by the Chinese-Russian partnership, are focusing on the south polar region, where the sun is never high over the horizon and the bottoms of some craters lie in permanent shadows. Over the years, NASA has financed nuclear reactor research, including the awarding of three $5 million contracts in 2022 to companies developing initial designs. Those designs were smaller, producing 40 kilowatts and weighing under six metric tons. Want all of The Times? Subscribe.


CNN
2 hours ago
- CNN
CNN10 What happens if an asteroid hits the moon?
Today on CNN10: An asteroid being monitored by scientists has changed course... we explore what could happen next. Then, back on Earth, we visit ancient petroglyphs that were just discovered in Hawaii, before looking into why Chinese companies are clamoring to get their storefronts to the U.S. Then, Coy takes a field trip to Asheville, North Carolina to get an update on how the town is recovering after Hurricane Helene. All of this and more on today's CNN10!